CRISPR Therapeutics AG — Director's Dealing 2019

Jul 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-07-10

Reporting Person: Klein Lawrence Otto (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-07-10	Common Shares	M	11579	$5.86	Acquired	31579	Direct
2019-07-10	Common Shares	S	11579	$50.02	Disposed	20000	Direct
2019-07-11	Common Shares	M	8421	$5.86	Acquired	28421	Direct
2019-07-11	Common Shares	S	8421	$50.0144	Disposed	20000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-10	Stock Option (Right to Buy)	$5.86	M	11579	Disposed	2026-03-01	Common Shares (11579)	Direct
2019-07-11	Stock Option (Right to Buy)	$5.86	M	8421	Disposed	2026-03-01	Common Shares (8421)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.075, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.1525, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 23,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter.